Trial Profile
A Phase 2a Study of Ultratrace Iobenguane I 131 [iodine I 131 metaiodobenzylguanidine] in Patients With Relapsed/Refractory High-Risk Neuroblastoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Iobenguane (Primary)
- Indications Neuroblastoma
- Focus Adverse reactions
- Sponsors Molecular Insight Pharmaceuticals
- 18 Mar 2019 Results of a pooled analysis from NCT00339131; NCT00458952; NCT00874614; NCT00659984 trials presented at the 101st Annual Meeting of the Endocrine Society
- 02 Aug 2012 Actual end date Nov 2010 added as reported by ClinicalTrials.gov.
- 07 Oct 2010 Planned end date changed from 1 Oct 2009 to 1 Dec 2010 as reported by ClinicalTrials.gov.